legendbiotech.com (LEGN): Net earnings per share growth forecast for next year

Analyst 12-month EPS growth targets reflect current trends, with the metric currently standing at 868.70. The growth of Legend Biotech (LEGN) relies on the success of Carvykti, capacity expansion, and FDA approval. Its proprietary cell therapy establishes an unrivaled standard of care, ensuring a steady revenue stream. High barriers to entry in manufacturing and partnerships with industry behemoths solidify the company's leadership in oncology.

To build a defensive portfolio, fundamental screening relies on consensus forecasts for annual earnings growth rates, which measure expected capital expansion and the asset's margin of safety. In the case of Legend Biotech (LEGN), this projection for net income per share for year n+1 reflects the efficiency of scaling cancer therapy and cost reductions through partnerships, where any downward trend on the chart signals a loss of investment attractiveness.